Raymond James Financial’s Pacira BioSciences PCRX Stock Holding History

Raymond James Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.19M	Buy	52,677 +35,121	+200%	+$781K	﹤0.01%	3740
2025 Q4	$454K	Buy	+17,556	New	+$417K	﹤0.01%	4334
2025 Q3	–	Sell	-90,108	Closed	-$2.15M	–	6231
2025 Q2	$2.15M	Buy	90,108 +76,411	+558%	+$1.93M	﹤0.01%	3028
2025 Q1	$340K	Buy	13,697 +3,598	+36%	+$86.1K	﹤0.01%	4143
2024 Q4	$190K	Buy	+10,099	New	+$177K	﹤0.01%	4416

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's PCRX Position: Q1 2026 in Review

Raymond James Financial increased its Pacira BioSciences (PCRX) stake by 200% in Q1 2026, buying an estimated $781K and bringing the position to 52,677 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3740.

Raymond James Financial first reported a position in PCRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.15M in Q2 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Raymond James Financial held 52,677 shares of Pacira BioSciences worth $1.19M as of Q1 2026.
Raymond James Financial bought 35,121 Pacira BioSciences shares in Q1 2026, an estimated $781K.
Pacira BioSciences made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3740 holding.
Raymond James Financial first reported a position in Pacira BioSciences in Q4 2024 and has held it in 5 quarters since.
Raymond James Financial's Pacira BioSciences position peaked at $2.15M in Q2 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.